Oxion Biologics (Oxionbio) is a biotech startup founded in 2021 by a team of physician-scientists with previous bio-entrepreneur track records. Based in Stockholm, Sweden, our focus is to develop novel therapies targeting immune-mediated diseases. Our lead asset, OX-118, is a prospectively best-in-class monoclonal antibody targeting OX40L, with a wide spectrum of potential indications ranging from type 2 inflammatory diseases and complex autoimmune conditions to solid organ transplantation. Oxionbio additionally holds a portfolio of next-generation antibody derivatives. Through a seed round of 65MSEK (6MEUR), the Oxionbio team, based in Sweden, the US and Switzerland, has facilitated a rapid and cost-effective progression from pre-clinical validation toward clinical proof-of-concept, aiming to bring our OX-118 program to CTA/IND approval for first-in-human (FIH) studies in 2024. The team is currently implementing our IP strategy, steering CMC-related processes and evaluating CROs for our FIH phase 1/1b study. To this end, we are planning for a Series A funding round in late 2023 - early 2024, and are seeking to introduce our case to prospective investors and partners.